Enliven Therapeutics (NASDAQ:ELVN) Trading 4.8% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shot up 4.8% on Tuesday . The stock traded as high as $26.81 and last traded at $26.76. 168,941 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 253,850 shares. The stock had previously closed at $25.54.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Robert W. Baird initiated coverage on Enliven Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective on the stock. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday.

Enliven Therapeutics Trading Up 2.5 %

The firm has a fifty day moving average of $23.14 and a two-hundred day moving average of $21.71. The company has a market cap of $1.23 billion, a PE ratio of -14.14 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other news, COO Anish Patel sold 17,475 shares of Enliven Therapeutics stock in a transaction on Friday, July 12th. The stock was sold at an average price of $25.07, for a total value of $438,098.25. Following the completion of the transaction, the chief operating officer now directly owns 376,552 shares in the company, valued at $9,440,158.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Anish Patel sold 17,475 shares of the stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $25.07, for a total value of $438,098.25. Following the sale, the chief operating officer now directly owns 376,552 shares of the company’s stock, valued at $9,440,158.64. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the sale, the insider now owns 1,077,936 shares in the company, valued at approximately $24,242,780.64. The disclosure for this sale can be found here. Insiders have sold 119,555 shares of company stock valued at $2,972,270 in the last 90 days. 29.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently modified their holdings of ELVN. China Universal Asset Management Co. Ltd. boosted its stake in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after buying an additional 3,189 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in Enliven Therapeutics in the first quarter worth about $167,000. Baker BROS. Advisors LP purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $2,020,000. Blackstone Inc. bought a new position in shares of Enliven Therapeutics in the 1st quarter worth approximately $443,000. Finally, Janus Henderson Group PLC boosted its position in shares of Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.